Supportive Care

MABp1, a novel anti–interleukin 1-alpha antibody, was safe, well-tolerated, and demonstrated a significant impact on symptoms compared with placebo for patients with advanced colorectal cancer.

The FDA has granted a breakthrough therapy designation to ruxolitinib for the treatment of patients with acute graft-versus-host disease.

eContour is a novel, web-based, interactive contouring resource that aims to facilitate access to decision support through high-yield radiation treatment recommendations that are free and available at the point of care.

An analysis of over 28,000 patients younger than 65 with incurable cancers found that approximately three-fourths of them received aggressive care within the last 30 days of life and one-third died in the hospital.

As the end of my hematology/oncology fellowship draws near, I am reminded every day that oncology is not about winning or losing.

Early palliative care integrated with oncology care benefits not only patients with cancer but also family caregivers.

The new generation of drugs that have emerged as part of antiemetic cocktails have demonstrated greater success in preventing and controlling CINV but the symptoms still present significant obstacles in anticancer therapy.